Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
The high-risk, high-reward nature of the Russell 2000 makes stock selection critical, and we’re here to guide you toward the right ones. Keeping that in mind, here is one Russell 2000 stock that could be a breakout winner and two that may struggle to keep up.
Two Stocks to Sell:
Progyny (PGNY)
Market Cap: $1.98 billion
Pioneering a data-driven approach to family building that has achieved an industry-leading patient satisfaction score of +80, Progyny (NASDAQ: PGNY) provides comprehensive fertility and family building benefits solutions to employers, helping employees access quality fertility treatments and support services.
Why Do We Think Twice About PGNY?
- Weak unit sales over the past two years indicate demand is soft and that the company may need to revise its strategy
- Subscale operations are evident in its revenue base of $1.31 billion, meaning it has fewer distribution channels than its larger rivals
- Low returns on capital reflect management’s struggle to allocate funds effectively
At $26 per share, Progyny trades at 12.1x forward P/E. Check out our free in-depth research report to learn more about why PGNY doesn’t pass our bar.
Lemonade (LMND)
Market Cap: $4.17 billion
Built on the principle of giving back unused premiums to charitable causes selected by policyholders, Lemonade (NYSE: LMND) is a technology-driven insurance company that offers homeowners, renters, pet, car, and life insurance through an AI-powered digital platform.
Why Does LMND Worry Us?
- Annual earnings per share growth of 8% underperformed its revenue over the last five years, showing its incremental sales were less profitable
- Annual book value per share declines of 18.4% for the past five years show its capital management struggled during this cycle
- Negative return on equity shows that some of its growth strategies have backfired
Lemonade’s stock price of $53.78 implies a valuation ratio of 8.6x forward P/B. To fully understand why you should be careful with LMND, check out our full research report (it’s free).
One Stock to Watch:
MediaAlpha (MAX)
Market Cap: $665.9 million
Powering nearly 10 million consumer referrals each month in the insurance marketplace, MediaAlpha (NYSE: MAX) operates a technology platform that connects insurance carriers with high-intent consumers shopping for property, casualty, health, and life insurance products.
Why Does MAX Stand Out?
- Annual revenue growth of 57% over the last two years was superb and indicates its market share increased during this cycle
- Adjusted operating margin expanded by 3.5 percentage points over the last five years as it scaled and became more efficient
- Earnings growth has trumped its peers over the last two years as its EPS has compounded at 171% annually
MediaAlpha is trading at $12.58 per share, or 9.7x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
